Article Text
Therapeutics
Cost-effectiveness analysis
Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA
Statistics from Altmetric.com
Footnotes
-
Competing interests WAD has received unrestricted funding from Eli Lilly Australia to investigate the economic impact of weight change among patients with type 2 diabetes treated with antidiabetic agents.